Combining liquid biopsy and functional imaging analysis in metastatic castration‐resistant prostate cancer helps predict treatment outcome

Plasma tumour DNA (ptDNA) is a potential early noninvasive biomarker of treatment outcome in metastatic castration‐resistant prostate cancer (mCRPC). Herein, we investigated whether pretreatment ptDNA levels reflect metabolic tumour burden in mCRPC and better predict treatment outcome in combination...

Descripción completa

Detalles Bibliográficos
Autores principales: Conteduca, Vincenza, Scarpi, Emanuela, Caroli, Paola, Lolli, Cristian, Gurioli, Giorgia, Brighi, Nicole, Poti, Giulia, Farolfi, Alberto, Altavilla, Amelia, Schepisi, Giuseppe, Matteucci, Federica, Paganelli, Giovanni, De Giorgi, Ugo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8763654/
https://www.ncbi.nlm.nih.gov/pubmed/34657387
http://dx.doi.org/10.1002/1878-0261.13120

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8763654/
https://www.ncbi.nlm.nih.gov/pubmed/34657387
http://dx.doi.org/10.1002/1878-0261.13120

Ejemplares similares